| Variables |
PEG-IFN alfa-2a |
PEG-IFN alfa-2b |
P* |
| (n=402, 60.8%) |
(n=259, 39.2%) |
| Genotype 1 (n=416), n (%) |
254 (61.1) |
162 (38.9) |
|
| Age, years† |
49 ± 11 |
51 ± 11 |
0.26 |
| >50 years, n (%) |
121 (47.6) |
83 (51.2) |
0.48 |
| Gender (male), n (%) |
154 (60.6) |
100 (61.7) |
0.74 |
| Weight (Kg) |
67 ± 12 |
66 ± 11 |
0.93 |
| ≥ 75kg, n (%) |
48 (18.9) |
34 (21.0) |
0.62 |
| BMI (Kg/m2)† |
24.3 ± 3.2 |
24.4 ± 3.1 |
0.81 |
| WBC (/mm3)† |
5.5 ± 2.1 |
5.2 ± 1.6 |
0.11 |
| Hemoglobin (g/dL)† |
13.9 ± 1.8 |
13.9 ± 1.7 |
0.72 |
| Platelet (×103/mm3)† |
173 ± 72 |
167 ± 71 |
0.46 |
| ALT (IU/L)† |
104 ± 86 |
94 ± 80 |
0.26 |
| HCV RNA (IU/mL)† |
2.9×106 ± 1.1×106 |
4.8×106 ± 1.9×106 |
0.24 |
| Fibrosis (stage), F0-2/F3-4, n (%)§ |
62/43 (59.0/41.0) |
18/6 (75.0/25.0) |
0.17 |
| Adherence, ≥ 80%/<80% |
171/83 (67.3/32.7) |
115/47(71.0/29.0) |
0.45 |
| Genotype 2 or 3 (n=235), n (%) |
141 (60.0) |
94 (40.0) |
|
| Age, years† |
49 ± 12 |
51 ± 11 |
0.19 |
| >50 years, n (%) |
61 (43.3) |
49 (52.1) |
0.19 |
| Gender (male), n (%) |
79 (56.0) |
54 (57.4) |
0.89 |
| Weight (Kg) |
65 ± 11 |
64 ± 10 |
0.51 |
| ≥ 75 kg, n (%) |
25 (17.7) |
11 (11.7) |
0.27 |
| BMI (Kg/m2)† |
23.8 ± 3.3 |
23.9 ± 2.7 |
0.98 |
| WBC (/mm3)† |
5.3 ± 1.5 |
5.1 ± 1.8 |
0.46 |
| Hemoglobin (g/dL)† |
14.2 ± 1.6 |
13.7 ± 1.5 |
0.06 |
| Platelet (×103/mm3)† |
177 ± 62 |
168 ± 65 |
0.32 |
| ALT (IU/L)† |
98 ± 88 |
90 ± 89 |
0.51 |
| HCV RNA (IU/mL)† |
2.0×106 ± 1.9×106 |
1.9×106 ± 1.0×106 |
0.83 |
| Fibrosis (stage), F0-2/F3-4, n (%)# |
51/10 (83.6/16.4) |
8/5 (61.5/38.5) |
0.12 |
| Adherence, ≥ 80%/<80% |
107/34 (75.9/24.1) |
78/16 (83.0/17.0) |
0.26 |
| Genotype others (n=10), n (%) |
7(70.0) |
3 (30.0) |
|
Abbreviations
HCV - Hepatitis C Virus; BMI - Body Mass Index; ALT - Alanine Aminotransferase; PEG-IFN-Peginterferon; F0-2- no or Insignificant Fibrosis; F3-4- Significant Fibrosis or
Cirrhosis
†mean ± standard deviation
§, # Data were available only in 129 (genotype 1) and 74 (genotype 2/3) patients who underwent liver biopsy before initiation of antiviral treatment. |
